Athersys to Participate in Two Upcoming Healthcare Conferences
April 01 2019 - 1:00PM
Athersys, Inc. (NASDAQ: ATHX) announced today the Company’s
participation in two upcoming biotechnology and healthcare
conferences. On April 4th, Athersys will be part of the William
Blair 3rd Annual Late-Stage Therapeutics Conference taking place in
New York City. This event consists of panel discussions focused on
healthcare issues specific to companies in Phase 3 clinical
development or in the early stages of launching a new therapy. In
addition, companies will conduct one-on-one management meetings
with institutional funds attending the conference.
The week after, Gil Van Bokkelen, Chairman and CEO, will present
a corporate overview at the 18th Annual Needham Healthcare
Conference at the Westin Grand Central in New York City. The
presentation is scheduled for April 9, 2019 at 10 am ET. The
company will also engage in meetings with other institutional
representatives at the conference.
A live webcast of the Needham conference presentation can be
accessed by visiting the events page in the investors section of
the Company’s website at www.athersys.com. An archived replay of
the webcast will be available on the Company’s website after the
conference for a limited time.
Institutional investors interested in arranging a meeting with
the Company’s management during the Needham conference should
contact the conference coordinators at
conferences@needhamco.com or call 212-705-0403.
About Athersys
Athersys is an international biotechnology company engaged in
the development of therapeutic products designed to extend and
enhance the quality of human life. The Company is developing its
MultiStem® cell therapy product, a patented, adult-derived
“off-the-shelf” stem cell product, initially for disease
indications in the neurological, cardiovascular, and inflammatory
and immune disease areas, and has several ongoing clinical trials
evaluating this potential regenerative medicine product. Athersys
has forged strategic partnerships and a broad network of
collaborations to further advance MultiStem cell therapy toward
commercialization. More information is available at
www.athersys.com.
William (B.J.) LehmannPresident and Chief Operating OfficerTel:
(216) 431-9900bjlehmann@athersys.com
Karen HunadyDirector of Corporate Communications &
Investor RelationsTel: (216) 431-9900khunady@athersys.com
David SchullRusso Partners, LLCTel: (212) 845-4271 or (858)
717-2310David.schull@russopartnersllc.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2023 to Apr 2024